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Abstract
Background: The WBRTMel trial is a multinational, open-label, phase III randomised controlled trial comparing
whole brain radiotherapy (WBRT) to observation following local treatment of one to three melanoma brain metastases
with surgery and/or stereotactic irradiation. The primary trial endpoint was to determine the effect of adding WBRT to
local treatment on distant intracranial control, and the secondary endpoints were neurocognitive function,
quality of life (QoL), performance status, overall survival, death from intracranial causes, death from melanoma
and cost-effectiveness.
Objective: The objective of this update is to outline and publish the pre-determined statistical analysis plan
(SAP) before the database lock and the start of analysis.
Methods: The SAP describes basic analysis principles, methods for dealing with a range of commonly encountered
data analysis issues and the specific statistical procedures for analysing efficacy and safety outcomes. The SAP was
approved after closure of recruitment and before completion of patient follow-up. It outlines the planned primary
analyses and a range of subgroup and sensitivity analyses regarding the clinical and QoL outcomes. Health economic
outcomes are not included in this plan but will be analysed separately. The SAP will be adhered to for the final data
analysis of this trial to avoid analysis bias arising from knowledge of the data.
Results: The resulting SAP is consistent with best practice and will allow open and transparent reporting.
Conclusion: We have developed a SAP for the WBRTMel trial which will be followed to ensure high-quality standards
of internal validity to minimise analysis bias.
Trial registration: ANZ Clinical Trials Registry, ACTRN12607000512426. Registered on 9 October 2007. ClinicalTrials.gov,
NCT01503827. Registered on 4 January 2012. Trial group reference numbers ANZMTG 01.07, TROG 08.05.
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Brain metastases are a common cause of death in pa-
tients with melanoma. The use of whole brain radiother-
apy (WBRT) after excision and/or stereotactic
radiosurgery (SRS) for melanoma brain metastases is
variable because of the lack of high-quality evidence to
guide practice. The trial’s rationale, feasibility and proto-
col were previously published [1–3]. In brief, the pri-
mary trial endpoint was to determine the effect of
adding WBRT to local treatment on distant intracranial
control, and the secondary endpoints were neurocogni-
tive function (NCF), quality of life (QoL), performance
status, overall survival, death from intracranial causes,
death from melanoma and cost-effectiveness. In con-
cordance with clinical trial requirements, the study was
prospectively registered (ACTRN12607000512426 and
NCT01503827). The trial completed the target accrual
in September 2017, and the final participant will be
followed up for at least 24 months.
Purpose of the analyses
The statistical analyses will assess the clinical endpoints
and safety of WBRT compared with the observation fol-
lowing excision and/or SRS.
Study objectives and endpoints
Study objectives
This trial aims to improve the treatment of brain metas-
tases for patients with stage IV melanoma by using
WBRT to improve disease control and maintain cogni-
tive performance and QoL.
Endpoints
Primary endpoint
The primary endpoint of the study is defined as distant
intracranial failure within 12 months of randomisation.
Distant intracranial failure is evaluated through magnetic
resonance imaging (MRI) assessment, as reported by
participating institutions, and is defined as new lesions
appearing 1 cm or more from previous index metastases,
coded as a binary outcome of success or failure.
Key secondary endpoint
The main NCF endpoint is decline in the mean raw
score of the Hopkins Verbal Learning Test-Revised
(HVLT-R) with Delayed Recall at 4 months, using (1)
relative change defined as ΔHVLT = 100*(HVLTB –
HVLTF) ÷ HVLTB, where indexes B = baseline and F = a
pre-specified follow-up time point [4], and (2) Reliable
Change Index (RCI) defined as a decline of ≥ 5 points
from baseline [5].
Secondary endpoints
Several secondary endpoints are assessed during the
study.
 Neurocognitive decline will be computed for HVLT-
R (Total Recall, Delayed Recall, Delayed
Recognition), Controlled Oral Word Association
Test, Trail Making Test Parts A and B, Stroop Color
and Word Test (Adult Version, Stroop Color, Stroop
Word, Stroop Color-Word, Stroop Interference), and
Digit Span (total score) [6, 7].
 Time to cognitive failure is defined as the time from
randomisation to date of first cognitive failure on
any of the NCF tests or death for patients who die
due to an intracranial cause prior to assessment or
NCF for patients who were alive but could not
complete the neurocognitive test due to neurological
disability. Cognitive failure for patients with NCF
assessment scores will be analysed using both raw
and standardised scores and defined by a significant
change in the RCI. Patients without neurognitive
failure are censored at their last date of contact.
 Distant intracranial failure within 3, 6 and 9 months
of follow-up and over the entire study period
(see primary endpoint definition)
 Time to distant intracranial failure as determined by
MRI
This is defined as the time to recurrence of disease
to a distance of 1 cm or more from previously treated
metastases from the date of randomisation. It is mea-
sured by the time difference between the randomisa-
tion MRI and intracranial failure MRI identifying
recurrence.
 Time to local intracranial failure as determined by MRI
This is defined as the time to recurrence of disease
within 1 cm of previously treated metastases from the
date of randomisation. It is measured by the time differ-
ence between the randomisation MRI and intracranial
failure MRI identifying recurrence. Local intracranial
failure rates within 3, 6, 9 and 12months of follow-up
and over the entire study period will also be computed.
 Time to overall (first distant or local) intracranial
failure
This is determined through MRI from observable de-
terioration and is defined as the time to the first intracra-
nial recurrence of disease anywhere (distant or local) from
randomisation. Overall intracranial failure rates within 3,
Lo et al. Trials          (2019) 20:477 Page 2 of 13
6, 9 and 12months of follow-up and over the entire study
period will also be computed.
 Time to deterioration in performance status as
measured by the Eastern Cooperative Oncology
Group (ECOG) Performance Status
This is defined as the time that elapses between ran-
domisation and the first recorded worsening in ECOG
Performance Status. This increase is measured from the
randomisation visit ECOG Performance Status score.
 QoL outcomes
The outcomes are measured using the European
Organisation for the Research and Treatment of Cancer
(EORTC) Quality of Life Questionnaires (QLQs),
namely:
– EORTC QLQ-C30: This questionnaire has 30 items
arranged into nine scales and six single items. The
scales are divided into five function scales (physical,
role, cognitive, emotional, social function), three
symptom scales (fatigue, pain, nausea or vomiting)
and one global health status/QoL scale [8].The six
single items address specific symptoms: dyspnea,
appetite loss, insomnia, constipation and diarrhoea,
with one question addressing the financial impact of
the disease.
– EORTC QLQ-BN20 – Brain Cancer Module: This
questionnaire contains 20 items organised into
four scales: future uncertainty (four items), visual
disorder (three items), motor dysfunction (three
items) and communication deficit (three items),
and seven single items (headaches, seizures,
drowsiness, hair loss, itchy skin, weakness of legs,
bladder control) [9]
– EORTC EQ-5D-5 L: This consists of two
questionnaire systems: (1) the EuroQol visual
analogue scale (EQ VAS), which records the
respondent’s self-rated health on a 20-cm vertical,
visual analogue scale with endpoints labelled ‘Best
health you can imagine’ and ‘Worst health you
can imagine’ [10]; (2) the five dimensions
questionnaire (mobility, self-care, usual activities,
pain/discomfort and anxiety/depression), where
each dimension has five levels (no problems,
slight problems, moderate problems, severe
problems and extreme problems).
In addition to associated dimension/items used as
QoL outcomes, time to deterioration in health-related
QoL parameters will also be derived and compared be-
tween groups. The deterioration in health-related QoL
outcomes will be measured by the EORTC QLQ-C30
and QLQ-BN20 questionnaires. The primary QoL end-
point will be time to deterioration in role function from
randomisation, with deterioration defined as a decrease
of ≥10 points on a 0–100 scale persisting for at least 4
weeks. Secondary endpoints will be time to deterioration
in global QoL, drowsiness, communication difficulties,
motor dysfunction and social function items/domains.
 Survival endpoints
Two sets of survival endpoints are considered: (1)
overall survival defined as time to death due to any
cause and (2) disease-specific outcomes which include
time to death due to intracranial disease and other mel-
anoma-specific cause. Survival time is assessed from date
of randomisation to that of death. Patients remaining
alive or lost to follow-up will be censored at the date of
last contact.
 Neurocognitive assessments
The Global Deficit Score (GDS) derived from NCF
tests at each assessment point [11]. Cognitive impair-
ment is defined as a GDS of ≥ 0.5 [12].
Tertiary endpoints
Although not statistically powered for these endpoints,
this trial will provide a unique opportunity to assess ob-
servation vs. hippocampal avoidance (HA-WBRT) vs.
WBRT in a prospective fashion for NCF outcomes. In
particular, this analysis will add to the ongoing debate
on the impact of WBRT on NCF and intracranial control
[13, 14].
The following variables will be considered:
 Mean relative NCF change from baseline at 2, 4, 6
and 12 months based on:
 HVLT-R Delayed Recall
 HVLT-R Total Recall
 HVLT-R Delayed Recognition.
 Global cognitive deterioration survival based on the
definition of cognitive impairment of 1 standard
deviation (SD) in at least one of the following
cognitive tests: HVLT-R, Trail Making Test or
Controlled Oral Word Association.
The following definitions of cognitive impairment will
also be explored:
○ 2 SD decline in at least one cognitive test
○ 1 SD decline in at least two cognitive tests
○ 2 SD decline in at least two cognitive tests.
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Safety outcomes
Adverse events (AEs) and any AE reported as a serious
adverse event (SAE) will be included in this analysis. An
AE is any adverse change (developing or worsening)
from the patient’s pre-treatment condition, including
intercurrent illness. AEs are to be recorded at the base-
line visit and then every 2months at the follow-up visits
or until the patient experiences distant intracranial
failure.
In this trial an SAE is defined as any untoward medical
occurrence which occurs during or within 90 days of
randomisation and which:
1. Results in death
2. Is life-threatening
3. Requires in-patient hospitalisation or prolongation
of existing hospitalisation
4. Results in persistent or significant disability/
incapacity
5. Results in a congenital anomaly/birth defect
6. Is a medically important event or reaction
7. Is a grade 3 (National Cancer Institute [NCI]
Common Terminology Criteria for Adverse Events
[CTCAE] v4.03) toxicity
8. Could be related to radiation therapy.
The NCI CTCAE v4.03 was used to classify and grade
the intensity of AEs/SAEs and their relationship to study
treatment.
Study methods
General study design and plan
This is a multinational, open-label, stratified, 2-arm par-
allel phase III trial. Figure 1 shows the schema for the
trial.
Inclusion and exclusion criteria and general study
population
Patient population
Patients were recruited from participating multidiscip-
linary melanoma centres. Patients were identified via
routine scanning demonstrating asymptomatic metasta-
ses or following investigation of intracranial symptoms.
Inclusion criteria
Patients were included in the study only if they met all
of the following criteria:
1. One to three (1–3) intracranial metastases on MRI
from melanoma, locally treated with either surgical
excision and/or SRS. It was assumed that the
metastases were melanoma if the patient had
documented histological concurrent extracranial
disease that had already made the patient stage IV.
If the cerebral lesion(s) were the first presentation
of stage IV disease, then one metastasis had to be
histologically proven to be melanoma for the
patient to be included in the study.
2. Had a life expectancy of at least 6 months.
3. Aged 18 years or older.
4. WBRT must have been able to commence within 8
weeks of completion of local treatment and within
4 weeks of randomisation.
5. Able to have an MRI brain scan with contrast.
Estimated glomerular filtration rate (eGFR) was
adequate at the discretion of the radiologist and
capable of having gadolinium-containing contrast
medium for MRI (as per practice guidelines).
6. Completion of local treatment of all these
metastases no more than 6 weeks prior to
randomisation.
7. An ECOG Performance Status between 0 and 2 at
randomisation.
8. Computed tomography (CT) or positron emission
tomography (PET) scan of chest, abdomen and
pelvis as a minimum prior to randomisation. Scans
must have been taken within 12 weeks of
randomisation.
9. Serum lactate dehydrogenase (LDH) level must
have been ≤2× upper limit of normal.
10. Was able to provide written informed consent.
Fig. 1 Trial schema
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Exclusion criteria
Patients were excluded from the study for any of the fol-
lowing reasons:
1. Any untreated intracranial disease
2. Any previous intracranial treatment (surgical
excision and/or stereotactic irradiation treatment
and/or WBRT) prior to this diagnosis of
intracranial melanoma
3. Evidence of leptomeningeal disease on pre-local
treatment MRI scan
4. Patients with prior cancers, except for those:
(a) Diagnosed more than 5 years ago with no
evidence of disease recurrence within this time
(b) With successfully treated basal cell or squamous
cell skin carcinoma
(c) With carcinoma in situ of the cervix
5. With a medical or psychiatric condition that
compromises ability to give informed consent or
complete the protocol
6. (Women of childbearing potential) with a positive
urine pregnancy test (within 7 days of
randomisation into the trial).
In order to be eligible for the main study, patients
must have cleared all of the preceding inclusion and
exclusion criteria. If centres had access to intensity-mod-
ulated radiotherapy (IMRT) for patients with brain me-
tastasis, randomisation could occur before local
radiotherapy treatment to allow for the use of simultan-
eous integrated boost during WBRT (see the Interim
analyses and data monitoring section). In addition, pa-
tients were excluded from the neurocognitive and QoL
aspects of the study if their fluency of (oral and written)
English was less than year 8 standard.
Randomisation and blinding
Patients were randomised at a 1:1 ratio using an interactive
voice response (randomisation) system (IVRS). Randomisa-
tion was stratified by the following factors:
 Number of cerebral metastases (1 only vs. > 1)
 Presence or absence of extracranial disease (seen on
clinical review and/or imaging)
 Centre
 Sex (male vs. female)
 Planned whole brain radiotherapy dose, 30 Gray in
10 fractions (30 Gy/10#) or higher
 Age (< 65 or ≥ 65 years old)
Study variables
All parameters and their timing of collection are sum-
marised in Table 1.
Sample size
Assuming the proportion of patients having distant
intracranial metastases at 12 months post-randomisation
would be 55% in the local control arm (surgery and/or
SRS) and 33% in the WBRT arm, a total of 220 patients
provided more than 84% power to detect the absolute
reduction of 22%, allowing for up to 10% non-compli-
ance and a two-sided alpha of 5%.
The initial sample size was based on a total sample
size of 200 to achieve 80% to reach the study primary
objective. However, modern radiation therapy technolo-
gies to spare the hippocampus during WBRT became
available in some centres during the study. In addition,
phase 2 data showed that HA-WBRT was superior in
terms of NCF outcomes, a secondary but important end-
point of the study. The investigators felt that if the
option of HA-WBRT was not included, accrual would
suffer. Therefore, the sample size was increased by
protocol amendment from the initial 200 to 220 to en-
able the recruitment of a total of 27 patients treated with
HA-WBRT. A sample of 27 patients treated with HA-
WBRT would achieve 80% power to detect a mean rela-
tive decline ≤7.5% against 30% mean relative decline in a
historical control from baseline to 4 months. The sample
size calculation assumed an estimated SD of 0.41, and
the level of significance (alpha) was set to 5% using a
one-sided Wilcoxon test assuming that the actual distri-
bution is normal.
At the time of the protocol amendment, 27 January
2016, 190 patients were enrolled in the study; among
them 16 had HA-WBRT. Therefore, 11 extra HA-WBRT
patients were needed. We expected to accrue these add-
itional 11 HA-WBRT patients by enrolling a further 30
patients, bringing the total sample size to 220.
General considerations
The analysis principles are as follows:
1. All analyses will be conducted on an intention-to-
treat basis.
2. All randomised patients will be analysed in the
group to which they were assigned regardless of
protocol violations. The only exception will be
patients whose consent to use their data in the
analysis is withheld or withdrawn.
3. All tests will be two-sided with a nominal level of
alpha of 5%.
4. Treatment effect estimated as difference in means,
odds ratio, hazard ratio or subdistribution hazard
and their 95% confidence interval (CI) will be
reported for all outcomes.
5. Adjusted analyses including the stratification factors
will be performed as sensitivity analyses.
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Follow-up visit every 2 months (± 2 weeks);
MRI every 3 months (± 4 weeks)
Intracranial
failure





Urine pregnancy test X
eGFR X
MRI of brain X X X X X X X X X X X




X X X X X X X X X X X X X X
AE/SAE reporting X X X X X X X X X X X X X X
Medical history X
Physical examination X X X X X X X X X X X X X X
Systemic therapies X X X X X X X X X X X X X X
Steroid use X X X X X X X X X X X X X X
Participation in other
clinical trials
X X X X X X X X X X X X X X




X X X X X X X X X X X X X X
NCF assessments X X X X X X X X X X X X X X
WBRT For patients randomised to the WBRT treatment arm:
WBRT is to commence < 4 weeks from randomisation and no more than 8 weeks from completion of local brain
metastases treatment
For patients who receive salvage WBRT during follow-up:
Patients may undergo salvage WBRT at any time during the observation period, at the local investigator’s discretion
Beyond 24 monthsb
Patients who have experienced intracranial failure by 24 months
Follow-up visit every 2 months (± 2 weeks);
MRI every 3 months (± 4 weeks)
Patients who have NOT had an
intracranial failure by 24
months
Follow-up visit every 3 months
(± 2 weeks);
MRI every 6 months (± 4 weeks)
Intracranial
failure
26 27 28 30 32 33 34 36 38 39 40 42 44 45 46 48 27 30 33 36 39 42 45 48
MRI of brain X X X X X X X X X X X X X
Disease statusa Any imaging after randomisation will be as clinically indicated by local protocol or for suspicion of systemic progression
ECOG Performance
Status
X X X X X X X X X X X X X X X X X X X X X
AE/SAE reporting X X X X X X X X X X X X X X X X X X X X X
Physical examination X X X X X X X X X X X X X X X X X X X X X
Systemic therapies X X X X X X X X X X X X X X X X X X X X X
Steroid use X X X X X X X X X X X X X X X X X X X X X
Participation in other
clinical trials
X X X X X X X X X X X X X X X X X X X X X




X X X X X X X X X X X X X X X X X X X X X
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6. Subgroup analyses will be carried out irrespective of
whether there is a significant effect of treatment on
outcome.
7. P values will not be adjusted for multiplicity.
However, the outcomes are clearly categorised by
degree of importance (primary to tertiary), and a
limited number of subgroup analyses are pre-
specified.
8. All summary tables will be annotated with the total
population size relevant to each treatment group.
9. P values ≥ 0.001 will be reported to three decimal
places; P values less than 0.001 will be reported as
’< 0.001’. The mean, SD and any other statistics
other than quantiles will be reported to one decimal
place greater than the original data. Quantiles, such
as median, or minimum and maximum will use the
same number of decimal places as the original data.
Estimated parameters, not on the same scale as raw
observations (e.g. regression coefficients), will be
reported to three significant figures.
10. Analyses will be conducted primarily using SAS,
version 9.4 or later and R 3.4.1 or later.
Analysis population
The final analysis will include all patients who were ran-
domised and have all baseline assessments performed.
Subgroups
The primary endpoint and the secondary endpoints
(excluding the key secondary endpoint) will be assessed
for the following subgroups:
 One vs. more than one cerebral metastasis
 Presence of extracranial disease vs. none
 Patients aged < 65 years of age or ≥ 65 years of age
 Sex: male vs. female
 Treated with systemic therapy (No vs. prior to
randomisation vs. within 12 months after
randomisation)
 Treated with steroid (No vs. prior to randomisation
vs. within 12 months after randomisation)
Interim analyses and data monitoring
An independent Data and Safety Monitoring Committee
(DSMC) was established to monitor the occurrence of
serious clinical and biological events. The DSMC
reviewed unblinded data to examine patient characteris-
tics, treatment compliance, outcomes and safety events
once the first 100 patients had completed 12 months of
follow-up. Only DSMC members and statisticians com-
piling closed-session reports for board meetings have
had access to unblinded interim data and results. The
Haybittle–Peto boundary was used as a stopping guide-
line for efficacy to maintain an overall type I error rate
of 5% level [15]. The incidence of distant intracranial
failure over time was calculated using a risk analysis ac-
counting for extracranial melanoma progression and
death from any cause other than intracranial disease as
competing risks. Distant intracranial failure and death
from intracranial disease were counted as events. After
the interim review, the DSMC made the following rec-
ommendation in the closed minutes: The quality of the
data collection for the major endpoints of this study were
meeting an excellent standard, the pre-specified stopping
criteria have not been met, and recommended continu-
ation of the study.
Multinational multicentre study
This is a trial involving three countries (Australia,
Norway and the UK) in which 24 centres have contrib-
uted data for at least one patient. Although study centres
were included as a stratification factor in the randomisa-
tion scheme, analyses of primary and secondary efficacy
outcomes will not adjust for study centre, because it is
anticipated some centres may be too small and may not
contribute any events to the pooled data. However, if a
positive treatment effect on the primary composite out-
come or the component events emerges, study centres
will be combined by country (Australia, Norway and the
UK) to assess the homogeneity of the treatment effect
across countries. Potential heterogeneity will be tested
by including a treatment-by-country interaction term in
a multivariate model with treatment and country as the
main effects.
Data analysis
Demographic and baseline variables
A description of the following baseline characteristics will be
presented by treatment group. All continuous variables will
be summarised using the following descriptive statistics: n
Table 1 Table 1 Schedule of study parameters and collection: months 0–24 and beyond 24 months (Continued)
NCF assessments X X X X X X X X X X X X X X X X X X X X X
WBRT For patients randomised to the WBRT treatment arm:
WBRT is to commence < 4 weeks from randomisation and no more than 8 weeks from completion of local brain metastases
treatment
For patients who receive salvage WBRT during follow-up:
Patients may undergo salvage WBRT at any time during the observation period, at the local investigator’s discretion
a Disease status assessed by staging CT or PET scans
b Follow-up visits will continue beyond month 48 and until death
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(non-missing sample size), mean (SD), median (minimum –
maximum). The frequency and percentages (based on the
non-missing sample size) of observed levels will be reported
for all categorical measures.




3. Country of birth
4. Main language spoken at home
5. Indigenous status
6. Country of residence
7. Date primary melanoma diagnosed
8. Primary melanoma has been treated
9. Primary melanoma present at the time of
randomisation
10. Type of primary melanoma (cutaneous, mucosal,
choroidal, other)






17. Number of intracranial metastases at baseline
18. Number of extracranial disease sites at
randomisation
19. Planned total dose of whole brain radiotherapy
20. Number of years of education completed
21. Wide Range Achievement Test (WRAT) score
22. Work status at time of melanoma diagnosis
23. Reason if not working
24. Indicate level of income
25. Indicate source of that income
26. Health insurance status of the patient
Medical history
27. Local recurrence diagnosed in the past
28. Previous local recurrence treated
29. Local recurrence present at baseline
30. Regional recurrence diagnosed in the past
31. Previous regional recurrence treated
32. Regional recurrence present at baseline
33. Distant recurrence diagnosed in the past
34. Number of distant recurrences
35. Organ affected by distant disease
36. Surgery performed on the distant disease
37. Radiotherapy given at the site of distant disease
Intracranial disease at baseline
38. Intracranial disease present at baseline
39. Location(s) of intracranial lesion
40. Maximum dimension of lesions(s); Diameter 1




(c) Histopathology performed on the lesion
(d) Melanoma confirmed by haematoxylin and
eosin (H&E) staining
(e) Melanoma confirmed by S100 staining
(f ) Melanoma confirmed by Human Melanoma
Black (HMB45) staining
(g) Lesion treated with stereotactic irradiation
(h) Diameter of stereotactic volume treated
(millimetres)




(c) Histopathology performed on the lesion
(d) Melanoma confirmed by H&E staining
(e) Melanoma confirmed by S100 staining
(f ) Melanoma confirmed by HMB45 staining
(g) Lesion treated with stereotactic irradiation
(h) Diameter of stereotactic volume treated
(millimetres)




(c) Histopathology performed on the lesion
(d) Melanoma confirmed by H&E staining
(e) Melanoma confirmed by S100 staining
(f ) Melanoma confirmed by HMB45 staining
(g) Lesion treated with stereotactic irradiation
(h) Diameter of stereotactic volume treated
(millimetres)
(i) Dose of lesion (Grays)
Process measurement
The summary statistics will be produced in accordance
with the Demographic and baseline variables section by
follow-up visit (baseline, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20,
22, 24 months). Differences between groups at each fol-
low-up visit will be assessed using the mean difference
and its 95% CI for continuous variables and the odds
ratio along with the corresponding 95% CI for categor-
ical variables. The overall treatment effect will be esti-
mated using repeated measures mixed linear model
(MLM) analysis or generalised estimating equation
(GEE) methods as appropriate. The following variables
will be summarised:
1. Physical examination (ECOG Performance Status)
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2. Systemic therapies use
3. Steroid use
Treatment compliance
The assessment of treatment compliance in the WBRT
group includes:
1. Major variations
(a) Duration of radiotherapy treatment
(b) Total dose of WBRT
2. Minor variations
(a) Duration from randomisation to radiotherapy
(b) Maximum clinical radiotherapy dose to brain
CT venography (CTV)
(c) Minimum dose received
Each variable will be summarised by frequency and
percentages.
Efficacy analyses
Efficacy analyses will be conducted on the basis of
’intention to treat’ and will be stratified by treatment
group. Efficacy analysis will be adjusted with the four
stratification factors (one vs. more than one cerebral me-
tastasis, presence of extracranial disease vs. none, pa-
tients aged < 65 years of age or ≥ 65 years of age, sex:
male vs. female). All group comparisons will be two-
tailed with a 5% significance level. For efficacy time-to-
event outcomes, patients with incomplete follow-up who
did not experience a relevant outcome event will be
censored at the time of their last contact (that is, their
time data will contribute to analyses).
Primary outcome
The primary endpoint, defined as distant intracranial
failure within 12months of follow-up (binary failure/suc-
cess), will be compared using a Pearson chi-squared test.
In cases where the expected count per cell is less than 5,
Fisher’s exact test will be used. Overall treatment effect
will be summarised using the odds ratio and its 95% CI).
Absolute treatment effect (risk difference) will also be
computed. Treatment success was defined as patients
who did not experience distant intracranial failure within
12months after starting treatment. Patients who died
prior to the 12 months assessment without any distant
intracranial failure sign will also be considered as a suc-
cess. In addition, patients who experienced local failure
but died without clinical evidence of distant failure will
be recorded as a success. When patients have withdrawn
consent or have been lost to follow-up before the 12
months assessment, the last follow-up intracranial as-
sessment status will be used for the primary endpoint
analysis.
Key secondary outcomes
Neurocognitive endpoint is defined as decline in the
mean raw score of the Hopkins Verbal Learning Test-
Revised (HVLT-R) Delayed Recall at 4 months, using
mean relative change and Reliable Change Index (RCI).
The Global Deficit Score (GDS) derived from NCF
tests at each assessment point where cognitive impair-
ment is defined as a GDS of ≥0.5. The proportion of pa-
tients with cognitive impairment in each group
(Observation, HA-WBRT and WBRT) will be sum-
marised by frequency and rate with its two-sided 95%
Clopper–Pearson exact CI. The denominator will be de-
fined as the total number of patients for whom the GDS
is computed. No formal inference will be performed
given the study is not designed for a formal comparison
between groups. Table 2 shows the calculation of GDS.
Secondary outcomes
We will analyse distant intracranial failure at 3, 6 and 9
months and over the entire study follow-up period, and
local intracranial failure and overall intracranial failure
at 3, 6, 9 and 12months and over the entire study fol-
low-up period. Analysis will be produced in accordance
with the primary outcome.
Time-to-event outcomes All secondary time-to-event
outcomes with the exception of overall survival and time
to deterioration in performance status will be analysed
in the context of the competing risks [16]. For instance,
death from any other cause than intracranial disease will
Table 2 Calculation of GDS
Cognitive
domain
Test and output Calculation





1 = (A + B + C)/3
Verbal fluency Controlled Oral Word
Association:
A) Total Letter Fluency
B) Category Fluency
C) Written Fluency
2 = (A + B + C)/3
Information
processing
Trail Making Test A 3
Attention Digit Span total score 4
Executive
function
Trail Making Test B 5




D) Stroop Interference 7 = (5 + 6)/2
Total GDS 8 = (1 + 2 + 3 + 4 + 7)/5
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prevent observation of a distant intracranial event.
Therefore, the incidence of distant intracranial failure
over time will be calculated using risk analysis account-
ing for death from any cause other than intracranial dis-
ease as a competing risk. The incidence of intracranial
events between the treatment and observation arms will
be compared using Gray’s test for equality while ac-
counting for competing risks (non-intracranial death)
[17]. Other time-to-event endpoints include time to
local intracranial failure (competing with both death or
distant failure as local failure is captured only before dis-
tant failure), time to overall (first distant or local) intra-
cranial failure (competing with death), time to
melanoma death (competing with non-melanoma death)
and time to intracranial death (competing with other
causes of death). These endpoints will also be analysed
using a competing risks approach.
In addition, all time-to-event outcomes will be sum-
marised graphically over the entire study follow-up
period through (1) Kaplan–Meier methods with log-rank
test stratified with the four stratification factors to assess
the differences between treatment arms and (2) a cumu-
lative incidence function for competing risk outcomes,
with Gray’s test for differences between treatment arms.
Hazard ratios using the Cox proportional hazard model
stratified with the four stratification factors, or subdistri-
bution hazard ratios using the Fine and Gray model
adjusted with the four stratification factors and their as-
sociated 95% CIs will be displayed in corresponding
figures as appropriate.
Overall survival The outcome will be described using
the product limit method of Kaplan–Meier. Survival
curve distribution differences between treatment groups
will be tested using the log-rank test. Hazard ratios and
corresponding 95% CIs will be computed using the Cox
proportional hazard model. The validity of the propor-
tional hazards assumption will be tested using Schoenfeld
residuals plots and corresponding test statistics. In con-
trast, if the proportional hazard assumption is violated (i.e.
the hazard ratio is changing over time), an alternative ro-
bust measure known as restricted mean survival time
(RMST), which does not rely on a specific assumption,
will be generated in each arm. Then instead of hazard ra-
tio, the difference in RMST along with its 95% CI will be
computed to evaluate the potential benefit of WBRT ef-
fects over the study duration.
Time to deterioration in performance status The ana-
lysis will be produced in accordance with the overall sur-
vival outcome analysis.
Time to deterioration in health-related quality of life
(QoL) parameters This outcome is measured by
EORTC QLQ-C30 with Brain Cancer Module (EORTC
QLQ-BN20) questionnaires. The completion rates for
quality of life questionnaires (QLQs) at the baseline visit
and at each 2 monthly follow-up visit will be determined
for each treatment group together with descriptive sum-
maries of scores. The cumulative incidence function will
be used to describe patterns of deterioration in health-
related QoL. A significant difference between groups will
be tested using Gray’s test.
QoL outcomes Utility-based QoL will be derived from
QLQ-C30 using the McKenzie mapping algorithm. EQ-
5D-5 L utilities will be calculated using the Australian
tariff [18]. The continuous utility endpoints will be sum-
marised by mean (SD) and stratified by assessment time
points (baseline, 2–48months) and by treatment group
[19]. The mean difference between the two arms and
their corresponding 95% CI will be provided at each as-
sessment time point. The average effect of the interven-
tion on each continuous outcome, over the entire study
period, will be estimated through an MLM with random
intercept, adjusting with associated baseline score, time
(categorical) and interaction between treatment and
time. In addition, an estimate of the intervention effect
adjusted for the four stratification factors (one vs. more
than one cerebral metastasis, presence of extracranial
disease vs. none, patients age < 65 vs. ≥ 65 years old, and
sex: male vs. female) will also be reported.
Categorical dimension/items will be analysed using
Likert-type scales and stratified by treatment group.
Deterioration in neurocognitive function (NCF) The
main NCF endpoint will be defined as a decline in the
mean score of the HVLT-R Delayed Recall at pre-speci-
fied follow-up visits. The proportion of patients complet-
ing NCF assessments at the baseline visit and at each 2
monthly follow-up visit will be determined for each of
the treatment groups (WBRT and Observation) together
with a descriptive summary of raw, standardised Z-
scores, a composite Z-score and GDS scores. The sum-
mary statistics will be produced in accordance with the
Process measurement section by follow-up visit (2, 4, 6,
8, 10 and 12 months). These will be standardised adjust-
ing for age, education and gender, and analysed for
change from baseline to pre-specified assessment visit.
Decline will be defined using the RCI [6, 7] and will also
be compared between the arms. Mean score changes
and 95% CI will also be represented graphically from
baseline over time. The overall effect of the intervention
on each continuous NCF variable will be estimated
through an MLM with random intercept, adjusting with
associated baseline score, time (categorical) and also
interaction between treatment and time. Overall effect
for categorical NCF variables will be estimated using
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GEE regression with a log-binomial link. The following
variables will be summarised:
1. HVLT
2. Controlled Oral Word Association Test
3. Trail Making Test Parts A and B
4. Stroop Color and Word Test (Adult Version)
5. Digit Span.
All analyses will be based on available data
(complete case). However, if more than 10% of the
data are missing for an outcome, a multiple imput-
ation method will be carried out as a sensitivity
method assuming data are missing at random (MAR).
The MAR assumption indicates that the missingness
mechanism depends on the observed outcome but
not on the missing outcome, which seems an appro-
priate assumption in this study [20].
Exploratory analyses will be conducted adjusting for
prognostic factors. Other time-to-event endpoints will
also be analysed using similar methods. Time to deteri-
oration in NCF will be analysed using both raw and
standardised scores and defined by a significant change
in the RCI (decline of ≥ 5 points from baseline). Out-
comes will be analysed using a competing approach as-
suming deterioration in NCF is competing with any
failure (local/distant intracranial failure or death).
Exploratory efficacy analyses
Subgroup analysis
The subgroup analyses will assess potential differences
in treatment effects, through an interaction effect. Evi-
dence of heterogeneity of treatment effects among sub-
groups will be demonstrated by the level of statistical
significance of the interaction term between treatment
group and subgroup using either a logistic regression
(for a binary outcome) or Cox regression (Overall sur-
vival) using a threshold of significance of 0.05. The sub-
group analyses will remain exploratory and hypothesis-
generating given the study is not specifically powered to
test any subgroup. Results will be presented as forest
plots with P values for heterogeneity (interaction test)
for each pair of subgroups displayed.
Tertiary endpoints
Exploratory analysis will be performed by simultaneously
comparing Observation vs. HA-WBRT vs. WBRT on the
variables listed below. Time-to-event outcomes will be
analysed in accordance with the Efficacy Analyses
section using a competing risks model or the Cox pro-
portional hazard model as appropriate. The cumulative
incidence function or Kaplan–Meier survival curves will
be provided as appropriate. Test of difference between
the three groups will be performed using one-way
analysis of covariance (ANCOVA) for continuous vari-
ables. For categorical variables, GEE regression with a
log-binomial link will be used. All models will be ad-
justed with their baseline measurements and will include
the following variables:
1. Global cognitive deterioration survival
2. Time to local intracranial failure
3. Time to distant intracranial failure
4. Time to overall survival
5. Deterioration in NCF measured as a significant
deterioration compared with baseline (5-point drop)
at 2, 4, 6, 8, 10 and 12 months in:
(a) HVLT-R Delayed Recall
(b) HVLT-R Total Recall
(c) HVLT-R Delayed Recognition.
Deterioration in NCF will be represented graphically
from baseline over time.
The preceding analysis will be replicated by the strati-
fication factors: one vs. more than one cerebral metasta-
sis, presence of extracranial disease vs. none, < 65 years
vs. ≥ 65 years of age, and sex: male vs. female.
Safety analyses
Safety outcomes will be analysed via frequencies for the
number of episodes of adverse events (AEs) and via fre-
quencies and percentages for the number of patients
with at least one episode per cohort (with the denomin-
ator being the total number of patients in each group).
All AEs (graded per Common Terminology Criteria
for Adverse Events [CTCAE]), even those not analysed,
will be reported stratified by treatment arm.
Conclusion
We have developed a statistical analysis plan (SAP)
for the ANZMTG 01.07 WBRTMel study. This plan
will be followed to ensure high-quality standards of
internal validity to minimise analysis bias. The SAP
was approved and signed off by the Trial Management
Committee on 1 October 2018. Following data integrity
checks of the primary and secondary 12 months out-
comes, the statistical analysis specified in the SAP was
started January 2019.
List of tables and figures
A list of proposed tables and a list of proposed figures
are displayed in this section. Reporting of the trial re-
sults is based on the International Conference on
Harmonisation of Technical Requirements for Registration
of Pharmaceuticals for Human Use (ICH) guideline for
reporting clinical trial results [21].
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Tables
 (1) Patient characteristics stratified by treatment arm
 (2) Medical history by treatment arm
 (3) Distant disease at baseline by treatment arm
 (4) Lesions summary (stratified by Lesion 1, Lesion
2, Lesion 3, etc.) by treatment arm
 (5) Physical examination by treatment arm
 (6) Systemic therapy and steroid use over treatment
by treatment arm
 (7) Treatment compliance by treatment arm
 (8) Primary and secondary distant intracranial
failure by treatment arm
 (9) Key secondary outcome
 (10) The EuroQol visual analogue scale (EQ VAS)
 (11) Deterioration in NCF over time by treatment
arm
 (12) Subgroup analysis (replicate Tables (8) and
(10) for each subgroup as defined in
Subgroups section)
 (13) Tertiary outcomes (replicate Tables (1) (8) and
(9), stratified by Observation vs. HA-WBRT vs.
WBRT)
 (14) AE and SAE summary by treatment arm.
Figures
 Trial flowchart (a Consolidated Standards of
Reporting Trials [CONSORT]-style flow diagram to
illustrate patient progression through the trial from
initial screening for eligibility to completion of the
final primary outcome assessment)
 Cumulative incidence function of distant intracranial
failure (competing with death) stratified by
treatment arm
 Cumulative incidence function of local intracranial
failure (competing with both death or distant failure
as local failure is captured only before distant
failure) stratified by treatment arm
 Cumulative incidence function overall (first distant
or local) intracranial failure (competing with death)
stratified by treatment arm
 Cumulative incidence function of melanoma death
(competing with other cause of death) stratified by
treatment arm
 Cumulative incidence function deterioration in
cognitive performance (competing with death)
stratified by treatment arm
 Cumulative incidence function of melanoma death
(competing with non-melanoma death) stratified by
treatment arm
 Cumulative incidence function of intracranial death
(competing with non-intracranial death) stratified by
treatment arm
 Cumulative incidence function of deterioration in
role function (competing with death)
 Cumulative incidence function of global QoL
(competing with death)
 Cumulative incidence function of drowsiness
(competing with death)
 Cumulative incidence function of communication
difficulties (competing with death)
 Cumulative incidence function of motor dysfunction
(competing with death)
 Cumulative incidence function of social function
items/domains (competing with death)
 Evolution of Hopkins Verbal Learning Test-
Revised, Delayed Recall (HVLT-R DR) and
Controlled Oral Word Association Test stratified
by treatment arm
 Evolution of HVLT-R, Total Recall and Delayed
Recognition stratified by treatment arm
 Evolution of Controlled Oral Word Association Test
stratified by treatment arm
 Evolution of Trail Making Test Parts A and B
stratified by treatment arm
 Evolution of Stroop Color and Word Test (Adult
Version) stratified by treatment arm
 Evolution of Digit Span (Forward and Backward)
stratified by treatment arm
 Kaplan–Meier overall survival curves by treatment
arm
 Cumulative incidence of local intracranial failure
(competing with distant intracranial failure and
death) stratified by Observation vs. HA-WBRT vs.
WBRT
 Cumulative incidence of time to distant intracranial
failure stratified by Observation vs. HA-WBRT vs.
WBRT
 Kaplan–Meier overall survival stratified by
Observation vs. HA-WBRT vs. WBRT
 Evolution of HVLT-R DR stratified by Observation
vs. HA-WBRT vs. WBRT
 Evolution of HVLT-R, Total Recall and Delayed
Recognition stratified by Observation vs. HA-WBRT
vs. WBRT
 Kaplan–Meier time to global cognitive deterioration
– HVLT-R
 Likert scale for EQ-5D-5 L dimensions/items
 Likert scale for EORTC QLQ-C30 dimensions/items
 Likert scale for EORTC QLQ-BN20 dimensions/
items
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